Low-Dose MRI Contrast Agent Gadoquatrane: 2026 FDA Approval, Uses & Imaging Impact

Key Takeaways

• The FDA approved gadoquatrane, sold as Ambelvist, in June 2026, making it the lowest-dose macrocyclic gadolinium contrast agent available in the United States.
• Its approved dose delivers 0.04 mmol gadolinium per kilogram, roughly 60% less than standard macrocyclic agents dosed at 0.1 mmol per kilogram.
• Gadoquatrane is cleared for contrast-enhanced MRI of the central nervous system and body in adults, children, and term neonates.
• Lower gadolinium doses support current safety guidance, but rising contrast MRI volumes increase demand for reliable physician supervision at imaging facilities.
• At ContrastConnect, we provide virtual contrast supervision that keeps outpatient and hospital imaging networks CMS-compliant while they scale contrast-enhanced MRI.

What Gadoquatrane's FDA Approval Changes for Contrast MRI

Gadoquatrane, branded as Ambelvist, became the lowest-dose macrocyclic gadolinium contrast agent available in the United States when the FDA cleared it in June 2026. Approval followed the Phase III QUANTI program, where blinded readers found its lesion visualization comparable to agents delivering roughly 60% less gadolinium per scan.

That dosing advantage lands at a meaningful moment. An estimated 12 to 18 million contrast-enhanced MRI scans are performed in the US each year, and volume keeps climbing as chronic conditions requiring repeat imaging become more common. Every one of those scans still requires physician supervision, a standard that strains facilities already navigating a national radiologist shortage.

ContrastConnect addresses that gap with radiologist-owned virtual contrast supervision, helping outpatient and hospital imaging networks maintain CMS compliance as they scale contrast MRI without adding on-site staffing.

ContrastConnect: Virtual Contrast Supervision That Never Misses

Built by Radiologists | 75,000+ Hours Monthly Contrast Exams | Trusted Nationwide

Built for Imaging Networks:

• Virtual Contrast Supervision: Radiologists provide immediate CMS-compliant supervision through a secure, HIPAA-compliant platform for outpatient facilities and hospital networks.
• Unmatched Experience: 130+ contrast reactions treated monthly with 3,900+ technologists certified.

The ContrastConnect Difference:

• ✓ Radiologist-owned with superior clinical expertise
• ✓ Always-on platform with guaranteed compliance
• ✓ Audit-ready documentation for CMS reviews
• ✓ Cost-efficient alternative to onsite staffing

Safety & Compliance You Trust:

Helping imaging centers reduce cancellations, extend hours, and scale operations without adding on-site radiologists. Response times measured in seconds.

Start Your Coverage Assessment →

What Is Gadoquatrane (Ambelvist)?

Gadoquatrane is an intravenous contrast agent given during MRI scans. It belongs to the macrocyclic class of gadolinium-based contrast agents (GBCAs), the more chemically stable group. Its molecule has a tetrameric structure that carries four gadolinium-binding units and produces high relaxivity, a measure of how strongly it enhances signal on the scan. This design lets a smaller gadolinium dose produce a diagnostic image.

Bayer markets the agent as Ambelvist. Bayer launched the first GBCA in 1988 and classifies gadoquatrane as its low-dose macrocyclic option.

Gadoquatrane's 2026 FDA Approval

Bayer submitted its New Drug Application for gadoquatrane in June 2025. The FDA accepted it for review that August and granted approval in June 2026. Gadoquatrane was first approved in Japan in March 2026. Approval in the United States was based on the Phase III QUANTI program, which consisted of two randomized, double-blind, active-comparator studies.

QUANTI CNS evaluated central nervous system pathology, and QUANTI OBR evaluated other body regions. Patients received either gadoquatrane at 0.01 mmol/kg or a macrocyclic comparator such as gadobutrol, gadoterate, or gadoteridol at 0.1 mmol Gd/kg. Blinded independent readers found lesion visualization scores and lesion counts with gadoquatrane similar to the higher-dose comparators in descriptive analyses. Pediatric use was supported by data from 93 patients aged 28 days to under 18 years.

Gadoquatrane Uses 

Gadoquatrane is indicated to detect and visualize lesions with abnormal vascularity in two regions: the central nervous system (brain, spine, and associated tissues) and the rest of the body (head and neck, thorax, abdomen, pelvis, and musculoskeletal system).

Gadoquatrane's recommended dose is 0.01 mmol/kg body weight, which delivers 0.04 mmol of gadolinium per kilogram. Patients with multiple sclerosis, other neurological or spinal conditions, and cancer often undergo repeated contrast MRI over years. A lower per-scan dose reduces their cumulative gadolinium exposure across many studies.

The table below compares Gadoquatrane with other macrocyclic agents.

Gadoquatrane Warning & Risk

Gadoquatrane carries a Boxed Warning covering two risks: serious adverse reactions from intrathecal administration, for which the agent is not approved, and nephrogenic systemic fibrosis in patients with impaired kidney function. It is contraindicated in patients with a history of severe hypersensitivity reactions to the agent.

Additional warnings cover hypersensitivity reactions, gadolinium retention, acute kidney injury, and interference with lesion visualization. Reported adverse reactions include dizziness, headache, injection site reactions, nausea, vomiting, feeling hot, tingling, and itching. A small share of contrast studies can trigger reactions, so a qualified clinical team must be available during each exam.

Lower Dose Does Not Remove the Per-Scan Supervision Requirement

Contrast MRI requires direct supervision. A physician must be immediately available to manage adverse reactions during each exam. This requirement, combined with a national radiologist shortage, has led some centers to cancel scans or limit hours.

On January 1, 2026, CMS made virtual direct supervision permanent for diagnostic tests. A supervising physician can now meet the immediate-availability standard through real-time, two-way audiovisual technology instead of on-site presence.

For multi-site networks, newer, safer agents increase the volume of contrast examinations per site, and permanent virtual supervision lets them cover that volume without an on-site radiologist at every location. Facilities can extend hours and reduce cancellations when their supervision meets CMS documentation and state requirements.

Scale Low-Dose Contrast MRI With ContrastConnect

Lower-dose agents such as gadoquatrane reduce gadolinium per scan, but they do not change the supervision every contrast study requires. At ContrastConnect, we provide real-time, CMS-compliant virtual contrast supervision so imaging networks can meet that requirement as contrast volumes grow.

Our radiologists cover exams across all operating hours with audit-ready documentation. Request a coverage assessment with us to keep facilities compliant while adopting newer low-dose imaging protocols.

Frequently Asked Questions (FAQs)

Is gadoquatrane the same thing as Ambelvist?

Yes. Gadoquatrane is the generic drug name, and Ambelvist is Bayer's registered brand name for it. Both terms refer to the same macrocyclic agent, so an order or protocol may list either one interchangeably.

How does gadoquatrane compare to gadopiclenol?

Gadoquatrane is dosed slightly lower than gadopiclenol, but both sit well below standard agents, so the gap matters less in practice than which agent a site stocks, the imaging protocol, and radiologist preference. Where those factors are equal, the lower per-scan gadolinium load can favor gadoquatrane for patients scanned repeatedly.

Is gadoquatrane safe for children and infants?

Yes, within its approved pediatric use, which extends to term neonates. The decision for each child still rests on kidney function, allergy history, and cumulative gadolinium exposure from prior scans, and a trained clinical team should remain available throughout every pediatric contrast exam.

Does contrast-enhanced MRI still require physician supervision in 2026?

Yes, and the newer detail is how that supervision can be delivered. Since January 1, 2026, a supervising physician can meet the immediate-availability standard virtually, but only where state law permits it, and the required real-time audiovisual documentation is kept for each exam. Audio-only contact does not satisfy the rule.

How does ContrastConnect support imaging centers using low-dose contrast agents?

At ContrastConnect, we provide radiologist-owned, always-on virtual contrast supervision for multi-site networks. Our platform delivers CMS-compliant oversight with audit-ready documentation and coverage across all operating hours. That lets imaging centers adopt newer agents, extend hours, and reduce cancellations without adding on-site radiologist staffing.‍

‍

Note: Information provided is for general guidance only and does not constitute medical, legal, or financial advice. Pricing estimates and regulatory requirements are current at the time of writing and subject to change. For personalized consultation on imaging center operations and virtual contrast supervision, contact ContrastConnect.